Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epithelial ovarian cancer.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL; National Comprehensive Cancer Network. Morgan RJ Jr, et al. Among authors: gray hj. J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. doi: 10.6004/jnccn.2011.0008. J Natl Compr Canc Netw. 2011. PMID: 21233246 No abstract available.
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Leslie KK, et al. Gynecol Oncol. 2012 Nov;127(2):345-50. doi: 10.1016/j.ygyno.2012.07.127. Epub 2012 Aug 7. Gynecol Oncol. 2012. PMID: 22885469 Free PMC article. Clinical Trial.
Ovarian cancer, version 3.2012.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network. Morgan RJ Jr, et al. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49. doi: 10.6004/jnccn.2012.0140. J Natl Compr Canc Netw. 2012. PMID: 23138163
Ovarian cancer, version 2.2013.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M; National comprehensive cancer networks. Morgan RJ Jr, et al. Among authors: gray hj. J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209. doi: 10.6004/jnccn.2013.0142. J Natl Compr Canc Netw. 2013. PMID: 24142821
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Kunos C, Deng W, Dawson D, Lea JS, Zanotti KM, Gray HJ, Bender DP, Guaglianone PP, Carter JS, Moore KN. Kunos C, et al. Among authors: gray hj. Int J Gynecol Cancer. 2015 Mar;25(3):484-92. doi: 10.1097/IGC.0000000000000380. Int J Gynecol Cancer. 2015. PMID: 25594147 Free PMC article. Clinical Trial.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. Coleman RL, et al. Among authors: gray hj. Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24. Gynecol Oncol. 2015. PMID: 25818403 Free PMC article. Clinical Trial.
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. Bender D, et al. Among authors: gray hj. Gynecol Oncol. 2015 Sep;138(3):507-12. doi: 10.1016/j.ygyno.2015.07.018. Epub 2015 Jul 15. Gynecol Oncol. 2015. PMID: 26186911 Free PMC article. Clinical Trial.
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Richardson DL, et al. Among authors: gray hj. JAMA Oncol. 2018 Feb 1;4(2):196-202. doi: 10.1001/jamaoncol.2017.4218. JAMA Oncol. 2018. PMID: 29242937 Free PMC article. Clinical Trial.
82 results